The latest launch time and market trends of baricitinib (baricitinib) generic drugs

Baricitinib, also known as baricitinib, is an oral JAK1/JAK2 inhibitor that is widely used to treat rheumatoid arthritis, severe alopecia (alopecia areata), severe COVID-19 and other indications. The drug was developed by Eli Lilly in the United States and was quickly promoted after being approved in Europe, the United States and other countries. In recent years, baricitinib has been officially approved for marketing in China and has been included in the national medical insurance directory, becoming an important treatment option for patients with chronic diseases such as rheumatoid arthritis. However, although it is included in medical insurance, the price of the original drug before medical insurance is still relatively high. For the specific post-reimbursement cost, the patient needs to consult the local hospital pharmacy.

In order to reduce the economic burden on patients, many countries have begun to develop and launch generic drugs of baricitinib. Among them, major generic drug producing countries such as India and Bangladesh took the lead in launching relevant versions. Bangladesh, in particular, has rapidly promoted the marketization of baricitinib generics in the past two years without having to follow a patent protection agreement. According to the latest news, multiple pharmaceutical factories in Bangladesh, such as Incepta, Beacon, etc., have successively launched generic versions of baricitinib since 2023 and are circulating in the international market, covering parts of Asia, Africa and the Middle East.

Compared with the original drug, the price of the generic version of baricitinib produced in Bangladesh is significantly more affordable. According to feedback from patients and information from overseas drug purchasing platforms, the price of a box of generic drugs in commonly used specifications (such as 4mg/ tablets) is only around 200 RMB, which is suitable as an economic alternative for patients with chronic diseases who take medicine for a long time. Although generic drugs are low in price, their medicinal ingredients are consistent with those of the original drugs. They have been widely used clinically in some countries and regions and have become an important supplement to the original drugs.

At present, if domestic patients want to obtain lower-priced treatment options, they can learn about formal overseas generic drug channels under the guidance of doctors, but they must pay attention to screening the quality and source of drugs to avoid purchasing fake and shoddy products through informal platforms. As domestic attention to the cost of treating chronic diseases increases, baricitinib generics are expected to gradually enter the market in more countries in the future, and even domestic generic versions may be approved for marketing in China, further reducing the drug burden on patients. Overall, the generic drug market for baricitinib is entering a stage of accelerated development, bringing broader and affordable treatment options to patients around the world.

Reference materials:https://www.drugs.com/